In their study, they found no Smad4 protein inactivation in stage I patients, 8% in stage II, 6% in stage III and 22% in stage IV patients, indicating that tumour progression correlates with Smad4 protein inactivation. The gene discussed is SMAD4; the disease is neoplasm.